Searched over 200M research papers
10 papers analyzed
These studies suggest that Chinese herbal medicines, including specific herbs and compounds like Fufang Shenhua tablet, astragali radix, Abelmoschus manihot, and quercetin, show potential in treating chronic kidney disease through anti-inflammatory, antioxidative, and antifibrotic effects, though more research is needed to confirm their safety and efficacy.
20 papers analyzed
Chronic kidney disease (CKD) is a significant global health issue, often progressing to end-stage renal disease (ESRD) with severe impacts on patients and healthcare systems. Traditional treatments primarily include angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers, which help manage hypertension and inflammation but are not always sufficient to halt disease progression. Consequently, there is a growing interest in alternative and complementary therapies, particularly traditional Chinese herbal medicines (TCHMs) and other natural products.
TCHMs have been used for centuries in the treatment of CKD, with modern research highlighting their potential benefits. These herbal medicines exhibit anti-inflammatory, antioxidative, anti-apoptotic, autophagy-mediated, and antifibrotic effects, which are crucial in managing CKD . For instance, the Fufang Shenhua tablet (SHT) and its active component Astragaloside IV (AS-IV) have shown significant anti-inflammatory and immunomodulatory properties, impacting various signaling pathways such as NF-κB, TLRs, and PI3K/AKT.
Despite promising results from in vitro and animal studies, the clinical evidence supporting TCHMs is limited due to small, non-randomized trials and variations in prescription patterns. However, some well-designed randomized controlled trials (RCTs) and meta-analyses have demonstrated the potential benefits of TCHMs as adjunctive treatments to conventional therapies . The need for more rigorous clinical trials to establish the safety and efficacy of these treatments remains a significant barrier.
The search for new pharmacological treatments for CKD has identified several promising agents currently in Phase II or III trials. These emerging drugs aim to address the limitations of existing therapies by targeting specific pathways involved in CKD progression. However, the transition from promising animal studies to effective human treatments has been challenging, with many agents failing to demonstrate consistent efficacy in clinical trials.
Natural products, such as epigallocatechin gallate (EGCG) from green tea and Ganoderma lucidum (GL) mushrooms, have shown potential in managing kidney diseases due to their antioxidant and anti-inflammatory properties. These natural compounds regulate various gene signatures and biological processes related to inflammation, ion signaling, and renal function, offering a complementary approach to traditional pharmacotherapy.
Quercetin, a natural flavonoid, has demonstrated protective effects against various kidney diseases, including nephrotoxicity, acute and chronic kidney injury, and diabetic nephropathy. Its antioxidant, antihypertensive, and antidiabetic properties make it a valuable candidate for CKD treatment.
Several other Chinese herbs have been identified for their therapeutic effects in CKD. These include Abelmoschus manihot, Salvia miltiorrhiza, Rhizoma coptidis, Tripterygium wilfordii, and Kudzu root. These herbs exhibit anti-fibrotic, anti-inflammatory, and antioxidative properties, promoting renal repair and regeneration.
The treatment landscape for CKD is evolving, with traditional Chinese herbal medicines and natural products offering promising complementary therapies. While preliminary studies and some clinical trials have shown beneficial effects, more rigorous research is needed to fully understand their mechanisms, efficacy, and safety. As the field progresses, these alternative treatments may provide valuable options for managing CKD and improving patient outcomes.
Most relevant research papers on this topic